DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
NYSE:DOCS - New York Stock Exchange, Inc. - US26622P1075 - Common Stock - Currency: USD
Taking everything into account, DOCS scores 7 out of 10 in our fundamental rating. DOCS was compared to 36 industry peers in the Health Care Technology industry. DOCS gets an excellent profitability rating and is at the same time showing great financial health properties. DOCS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make DOCS suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
DOCS had a positive operating cash flow in the past year.
Each year in the past 5 years DOCS has been profitable.
Each year in the past 5 years DOCS had a positive operating cash flow.
1.2 Ratios
DOCS has a better Return On Assets (17.65%) than 100.00% of its industry peers.
With an excellent Return On Equity value of 20.62%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 17.07%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DOCS had an Average Return On Invested Capital over the past 3 years of 14.17%. This is significantly above the industry average of 6.38%.
The 3 year average ROIC (14.17%) for DOCS is below the current ROIC(17.07%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.65% | ||
| ROE | 20.62% | ||
| ROIC | 17.07% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
Looking at the Profit Margin, with a value of 39.13%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DOCS's Profit Margin has improved in the last couple of years.
DOCS has a better Operating Margin (40.34%) than 100.00% of its industry peers.
In the last couple of years the Operating Margin of DOCS has grown nicely.
DOCS's Gross Margin of 90.20% is amongst the best of the industry. DOCS outperforms 97.22% of its industry peers.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.34% | ||
| PM (TTM) | 39.13% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so DOCS is still creating some value.
The number of shares outstanding for DOCS has been increased compared to 1 year ago.
Compared to 5 years ago, DOCS has more shares outstanding
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 40.63 indicates that DOCS is not in any danger for bankruptcy at the moment.
DOCS has a better Altman-Z score (40.63) than 97.22% of its industry peers.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 40.63 |
ROIC/WACC1.59
WACC10.7%
2.3 Liquidity
DOCS has a Current Ratio of 6.97. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
DOCS has a Current ratio of 6.97. This is amongst the best in the industry. DOCS outperforms 94.44% of its industry peers.
A Quick Ratio of 6.97 indicates that DOCS has no problem at all paying its short term obligations.
DOCS has a better Quick ratio (6.97) than 94.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.97 | ||
| Quick Ratio | 6.97 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.42% over the past year.
The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
DOCS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.97%.
Measured over the past years, DOCS shows a very strong growth in Revenue. The Revenue has been growing by 37.42% on average per year.
EPS 1Y (TTM)48.42%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%52%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%17.14%
3.2 Future
The Earnings Per Share is expected to grow by 17.53% on average over the next years. This is quite good.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.57% yearly.
EPS Next Y2.49%
EPS Next 2Y7.75%
EPS Next 3Y10.11%
EPS Next 5Y17.53%
Revenue Next Year10.68%
Revenue Next 2Y10.59%
Revenue Next 3Y10.54%
Revenue Next 5Y10.57%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 44.27, which means the current valuation is very expensive for DOCS.
Based on the Price/Earnings ratio, DOCS is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
DOCS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.30.
A Price/Forward Earnings ratio of 43.20 indicates a quite expensive valuation of DOCS.
61.11% of the companies in the same industry are more expensive than DOCS, based on the Price/Forward Earnings ratio.
DOCS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 36.06.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.27 | ||
| Fwd PE | 43.2 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DOCS is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
66.67% of the companies in the same industry are more expensive than DOCS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.95 | ||
| EV/EBITDA | 41.67 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)17.81
PEG (5Y)0.56
EPS Next 2Y7.75%
EPS Next 3Y10.11%
5. Dividend
5.1 Amount
No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
62.42
+0.37 (+0.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners93.81%
Inst Owner Change-0.04%
Ins Owners2.25%
Ins Owner Change-2.03%
Market Cap11.72B
Analysts76.15
Price Target62.73 (0.5%)
Short Float %4.3%
Short Ratio2.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.65%
Min EPS beat(2)30.62%
Max EPS beat(2)36.67%
EPS beat(4)4
Avg EPS beat(4)26.68%
Min EPS beat(4)15.86%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)24.85%
EPS beat(12)12
Avg EPS beat(12)22.9%
EPS beat(16)16
Avg EPS beat(16)34.8%
Revenue beat(2)2
Avg Revenue beat(2)4.77%
Min Revenue beat(2)1.38%
Max Revenue beat(2)8.16%
Revenue beat(4)4
Avg Revenue beat(4)4.65%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)6
Avg Revenue beat(8)2.85%
Revenue beat(12)8
Avg Revenue beat(12)1.88%
Revenue beat(16)12
Avg Revenue beat(16)3.35%
PT rev (1m)0.05%
PT rev (3m)-18.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.11%
EPS NY rev (1m)8.19%
EPS NY rev (3m)-0.02%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-2.59%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.27 | ||
| Fwd PE | 43.2 | ||
| P/S | 20.55 | ||
| P/FCF | 43.95 | ||
| P/OCF | 42.9 | ||
| P/B | 10.83 | ||
| P/tB | 11.82 | ||
| EV/EBITDA | 41.67 |
EPS(TTM)1.41
EY2.26%
EPS(NY)1.45
Fwd EY2.32%
FCF(TTM)1.42
FCFY2.28%
OCF(TTM)1.45
OCFY2.33%
SpS3.04
BVpS5.76
TBVpS5.28
PEG (NY)17.81
PEG (5Y)0.56
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.65% | ||
| ROE | 20.62% | ||
| ROCE | 20.77% | ||
| ROIC | 17.07% | ||
| ROICexc | 98.29% | ||
| ROICexgc | 186.54% | ||
| OM | 40.34% | ||
| PM (TTM) | 39.13% | ||
| GM | 90.2% | ||
| FCFM | 46.76% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexcg growth 3Y3.35%
ROICexcg growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 61.22% | ||
| Cap/Sales | 1.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.5% | ||
| Profit Quality | 119.52% | ||
| Current Ratio | 6.97 | ||
| Quick Ratio | 6.97 | ||
| Altman-Z | 40.63 |
F-Score9
WACC10.7%
ROIC/WACC1.59
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)48.42%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%52%
EPS Next Y2.49%
EPS Next 2Y7.75%
EPS Next 3Y10.11%
EPS Next 5Y17.53%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%17.14%
Revenue Next Year10.68%
Revenue Next 2Y10.59%
Revenue Next 3Y10.54%
Revenue Next 5Y10.57%
EBIT growth 1Y33.93%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year12.42%
EBIT Next 3Y11.62%
EBIT Next 5Y11.91%
FCF growth 1Y49.61%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y48.44%
OCF growth 3Y29.24%
OCF growth 5Y59.83%